X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7514) 7514
Publication (1069) 1069
Book Review (87) 87
Book Chapter (82) 82
Patent (49) 49
Dissertation (20) 20
Conference Proceeding (11) 11
Data Set (2) 2
Magazine Article (2) 2
Web Resource (2) 2
Book / eBook (1) 1
Presentation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5524) 5524
humans (4813) 4813
non-alcoholic fatty liver disease (3566) 3566
male (3470) 3470
fatty liver (2705) 2705
female (2595) 2595
gastroenterology & hepatology (2478) 2478
animals (2273) 2273
liver diseases (2176) 2176
liver (1919) 1919
insulin-resistance (1899) 1899
middle aged (1897) 1897
obesity (1783) 1783
metabolic syndrome (1684) 1684
steatohepatitis (1674) 1674
adult (1661) 1661
liver - pathology (1661) 1661
fibrosis (1609) 1609
insulin resistance (1541) 1541
nonalcoholic steatohepatitis (1495) 1495
risk factors (1428) 1428
mice (1418) 1418
fatty liver-disease (1380) 1380
non-alcoholic steatohepatitis (1380) 1380
liver - metabolism (1367) 1367
steatosis (1253) 1253
hepatic steatosis (1228) 1228
non-alcoholic fatty liver disease - pathology (1221) 1221
non-alcoholic fatty liver disease - metabolism (1168) 1168
inflammation (1167) 1167
nafld (1075) 1075
prevalence (1056) 1056
oxidative stress (968) 968
analysis (942) 942
biopsy (885) 885
aged (844) 844
gastroenterology and hepatology (811) 811
fatty liver - pathology (809) 809
nonalcoholic fatty liver disease (794) 794
disease models, animal (788) 788
disease (762) 762
nutritional and metabolic diseases (749) 749
digestive system diseases (737) 737
mice, inbred c57bl (728) 728
metabolism (722) 722
rodents (720) 720
nash (704) 704
diet (699) 699
non-alcoholic fatty liver disease - complications (699) 699
fatty liver - metabolism (681) 681
article (666) 666
diabetes (655) 655
liver cirrhosis (655) 655
body mass index (647) 647
hepatology (627) 627
non-alcoholic fatty liver disease - drug therapy (621) 621
disease progression (599) 599
endocrinology & metabolism (599) 599
non-alcoholic fatty liver disease - diagnosis (595) 595
non-alcoholic fatty liver disease - blood (580) 580
diagnosis (572) 572
cirrhosis (570) 570
non-alcoholic fatty liver disease - epidemiology (567) 567
non-alcoholic fatty liver disease - etiology (565) 565
lipids (562) 562
non-alcoholic fatty liver disease - genetics (557) 557
care and treatment (555) 555
fatty acids (548) 548
hepatocellular-carcinoma (547) 547
liver - drug effects (547) 547
biochemistry & molecular biology (539) 539
expression (536) 536
rats (536) 536
biomarkers - blood (532) 532
physiological aspects (532) 532
pathogenesis (524) 524
health aspects (520) 520
research (516) 516
association (514) 514
severity of illness index (513) 513
development and progression (504) 504
digestive system (498) 498
gene expression (495) 495
medicine (492) 492
pharmacology & pharmacy (490) 490
cholesterol (486) 486
natural-history (485) 485
insulin (484) 484
risk-factors (481) 481
medicine & public health (476) 476
risk (474) 474
research article (470) 470
obesity - complications (460) 460
liver cirrhosis - pathology (455) 455
fatty liver - etiology (446) 446
nutrition & dietetics (442) 442
gastroenterology (437) 437
medicine, research & experimental (436) 436
adolescent (433) 433
medical research (433) 433
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7399) 7399
Korean (53) 53
Japanese (47) 47
German (44) 44
Chinese (43) 43
Spanish (27) 27
French (23) 23
Russian (15) 15
Polish (5) 5
Czech (3) 3
Hungarian (2) 2
Italian (2) 2
Persian (2) 2
Ukrainian (2) 2
Danish (1) 1
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Liver International, ISSN 1478-3223, 01/2017, Volume 37, Issue S1, pp. 97 - 103
The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in the hepatocytes, which may be an isolated event (non‐alcoholic... 
non‐alcoholic steatohepatitis (NASH) | peroxisome proliferator‐activator receptor (PPAR) agonists | farnesoid X receptor (FXR) | non‐alcoholic fatty liver disease (NAFLD) | ROS (reactive oxygen species) | glucagon‐like peptide (GLP‐1) agonist | non-alcoholic fatty liver disease (NAFLD) | glucagon-like peptide (GLP-1) agonist | peroxisome proliferator-activator receptor (PPAR) agonists | non-alcoholic steatohepatitis (NASH) | VITAMIN-E | ACID | RANDOMIZED-TRIALS | AMERICAN ASSOCIATION | FATTY LIVER-DISEASE | WEIGHT-LOSS | GLUCAGON-LIKE PEPTIDE-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | PENTOXIFYLLINE | Hypoglycemic Agents - therapeutic use | Liver Cirrhosis - etiology | Liver - pathology | Liver Transplantation | Humans | Risk Factors | Non-alcoholic Fatty Liver Disease - therapy | Disease Progression | Randomized Controlled Trials as Topic | Liver Neoplasms - etiology | Non-alcoholic Fatty Liver Disease - complications | Thiazolidinediones - therapeutic use | Exercise | Diet | Fibrosis | Vitamin E - therapeutic use | Carcinoma, Hepatocellular - etiology | Liver diseases | Syngeneic grafts | Pathogenesis | Liver | Pioglitazone | Viruses | Hepatocellular carcinoma | Transplantation | Infections | Steatosis | Hepatitis | Cirrhosis | Fatty liver | Cell injury | Hepatocytes | Vitamin E | Hepatitis C virus | Hepatitis C | Tocopherol | Liver transplantation | Nonalcoholic fatty liver disease (NAFLD) | Farnesoid X receptor (FXR) | Glucagon-like peptide (GLP-1) agonist | Peroxisome proliferator-activator receptor (PPAR) agonists | Nonalcoholic steatohepatitis (NASH)
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 09/2015, Volume 114, Issue 11, pp. 1745 - 1755
Overnutrition, insulin resistance and an impaired intestinal barrier function are discussed as critical factors in the development of non-alcoholic fatty liver... 
Sodium butyrate | Reactive oxygen species | Hepatic inflammation | Non-alcoholic fatty liver disease | Inducible nitric oxide synthase | FIBROSIS | INDUCED HEPATIC STEATOSIS | CELLS | FATTY LIVER-DISEASE | REPERFUSION INJURY | ENDOTOXIN | TRANSCRIPTION | BARRIER FUNCTION | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | NUTRITION & DIETETICS | INFLAMMATION | Immunohistochemistry | Non-alcoholic Fatty Liver Disease - pathology | Intestinal Mucosa - metabolism | Liver - pathology | Tight Junction Proteins - genetics | Neutrophil Infiltration | Butyric Acid - therapeutic use | Liver - immunology | Intestinal Mucosa - immunology | Duodenum - metabolism | Female | Toll-Like Receptor 4 - antagonists & inhibitors | Tight Junction Proteins - metabolism | Biomarkers - metabolism | Duodenum - immunology | Signal Transduction | Liver - metabolism | Mice, Inbred C57BL | Non-alcoholic Fatty Liver Disease - immunology | Gene Expression Regulation | Toll-Like Receptor 4 - genetics | Non-alcoholic Fatty Liver Disease - metabolism | Diet, Western - adverse effects | Toll-Like Receptor 4 - metabolism | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Duodenum - pathology | Gastrointestinal Agents - therapeutic use | Non-alcoholic Fatty Liver Disease - prevention & control | Lipid Peroxidation | Dietary Supplements | Intestinal Mucosa - pathology | Hepatitis | Nutrition research | Rodents | Dietary supplements
Journal Article
Journal Article
Journal Article
Obesity Surgery, ISSN 0960-8923, 4/2011, Volume 21, Issue 4, pp. 431 - 439
Journal Article